Pharmaceutical CDMO Market Projected to Hit $270.3B by 2031, Driven by Outsourcing and Biologics Demand
Event summary
- The global pharmaceutical CDMO market is projected to grow from $191 billion in 2026 to $270.3 billion by 2031, a CAGR of 7.2%.
- Growth is driven by rising outsourcing of drug development and manufacturing, increasing demand for biologics and complex therapeutics, and advancements in manufacturing technologies.
- Key players like Lonza, Thermo Fisher Scientific, Catalent, Samsung Biologics, and WuXi AppTec are expanding capabilities in biologics and advanced therapy manufacturing.
- North America is the largest regional market, while Asia-Pacific is the fastest-growing region, with China seeing significant growth.
The big picture
The pharmaceutical CDMO market is expanding rapidly as pharmaceutical companies increasingly outsource drug development and manufacturing to focus on core R&D. The shift towards biologics and complex therapeutics is driving demand for specialized CDMO capabilities, while advancements in manufacturing technologies are enhancing efficiency and reducing speed-to-market. This trend is particularly pronounced in Asia-Pacific, where competitive production costs and expanding manufacturing infrastructure are fueling growth.
What we're watching
- Capacity Constraints
- Whether CDMOs can keep up with demand for specialized manufacturing facilities, particularly for biologics and advanced therapies.
- Regulatory Compliance
- How CDMOs will navigate increasing regulatory complexity and maintain compliance across multiple regions.
- Technological Advancements
- The pace at which CDMOs adopt single-use bioprocessing, automation, and AI-based process optimization to improve efficiency.
Related topics